Silence Therapeutics Plc (SLN):企業の財務・戦略的SWOT分析

◆英語タイトル:Silence Therapeutics Plc (SLN) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH36126FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Silence Therapeutics plc (Silence Therapeutics), formerly SR Pharma plc is a developer of therapeutics that channels gene silencing to cure life-threatening diseases. The company’s pipeline products include SLN124, SLN500 and SLN360. Its SLN124 is developed for the treatment of cardiovascular disease with high Lp(a); SLN500 for complement-medicated diseases and SLN360 for e-Thalassaemia and myelodysplastic syndrome. Silence Therapeutics also provides RNA interface that include short interfering RNA (siRNA) and messenger RNAs (mRNA). The company collaborates with pharmaceutical, biotechnology companies and academic research institutions. It operates in Germany and the UK. Silence Therapeutics is headquartered in London, the UK.

Silence Therapeutics Plc Key Recent Developments

Mar 30,2021: Silence Therapeutics Reports Full-year 2020 Results
Feb 26,2021: Silence Therapeutics and Mallinckrodt initiate work on third target as part of ongoing RNAi research collaboration for complement-mediated diseases
Jan 06,2021: Silence Therapeutics appoints Michael H. Davidson, MD, to Board of Directors
Jan 06,2021: Silence Therapeutics appoints Craig Tooman as Chief Financial Officer
Nov 02,2020: Silence Therapeutics appoints Dr. Marie Wikstrom

This comprehensive SWOT profile of Silence Therapeutics Plc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Silence Therapeutics Plc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Silence Therapeutics Plc – Key Information
Silence Therapeutics Plc – Overview
Silence Therapeutics Plc – Key Employees
Silence Therapeutics Plc – Key Employee Biographies
Silence Therapeutics Plc – Key Operational Heads
Silence Therapeutics Plc – Major Products and Services
Silence Therapeutics Plc – History
Silence Therapeutics Plc – Company Statement
Silence Therapeutics Plc – Locations And Subsidiaries
Silence Therapeutics Plc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Silence Therapeutics Plc – Business Description
Silence Therapeutics Plc – Corporate Strategy
Silence Therapeutics Plc – SWOT Analysis
SWOT Analysis – Overview
Silence Therapeutics Plc – Strengths
Silence Therapeutics Plc – Weaknesses
Silence Therapeutics Plc – Opportunities
Silence Therapeutics Plc – Threats
Silence Therapeutics Plc – Key Competitors

Section 3 – Company Financial Performance Charts

Silence Therapeutics Plc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Silence Therapeutics Plc, Key Information
Silence Therapeutics Plc, Key Ratios
Silence Therapeutics Plc, Share Data
Silence Therapeutics Plc, Major Products and Services
Silence Therapeutics Plc, History
Silence Therapeutics Plc, Key Employees
Silence Therapeutics Plc, Key Employee Biographies
Silence Therapeutics Plc, Key Operational Heads
Silence Therapeutics Plc, Other Locations
Silence Therapeutics Plc, Subsidiaries
Silence Therapeutics Plc, Key Competitors
Silence Therapeutics Plc, SWOT Analysis
Silence Therapeutics Plc, Ratios based on current share price
Silence Therapeutics Plc, Annual Ratios
Silence Therapeutics Plc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Silence Therapeutics Plc (SLN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Otsuka Pharmaceutical Co Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Otsuka Pharmaceutical Co Ltd (OPC), a subsidiary of Otsuka Holdings Co Ltd is a provider of healthcare products. The company offers products which include pocari sweat, pocari sweat ion water, oronamin c, calorie mate, nature made, jerubure, jarinea, five mini, amino-value, enerugen, jog mat …
  • MedStar Health:企業の戦略的SWOT分析
    MedStar Health - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • HST Global Inc (HSTC):企業の財務・戦略的SWOT分析
    Summary HST Global Inc (HST Global) is a biotechnology, health and wellness company that discovers and develops treatment for metabolic disorders including cancer and other life threatening illnesses. The company provides therapies for dysfunction, metabolic deficiencies, and disorders providing an …
  • Filinvest Development Corporation (FDC):企業の財務・戦略的SWOT分析
    Filinvest Development Corporation (FDC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Innoviva Inc (INVA):製薬・医療:M&Aディール及び事業提携情報
    Summary Innoviva Inc (Innoviva) develops and commercializes small molecule medicines. It focuses on products for various respiratory disorders. The company partners with GSK for the commercialization and development of all its products. It receives royalty payments for its collaboration with GSK. In …
  • SuppreMol GmbH-製薬・医療分野:企業M&A・提携分析
    Summary SuppreMol GmbH (SuppreMol), a subsidiary of Baxalta Inc, is a biopharmaceutical company that develops therapeutics in the areas of autoimmune, chronic inflammatory diseases, and allergies. The company’s lead drug candidate is extensively profiled in in-vitro, ex-vivo and in-vivo experiments. …
  • Marshall of Cambridge (Holdings) Ltd:企業の戦略・SWOT・財務情報
    Marshall of Cambridge (Holdings) Ltd - Strategy, SWOT and Corporate Finance Report Summary Marshall of Cambridge (Holdings) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Consolidated Construction Consortium Limited:企業の戦略・SWOT・財務情報
    Consolidated Construction Consortium Limited - Strategy, SWOT and Corporate Finance Report Summary Consolidated Construction Consortium Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • Cocrystal Pharma Inc (COCP):企業の財務・戦略的SWOT分析
    Summary Cocrystal Pharma Inc (Cocrystal Pharma), formerly Biozone Pharmaceuticals Inc, a subsidiary of MusclePharm Corp, is a clinical stage biotechnology company that discovers and develops novel antiviral therapeutics. The company provides treatments for chronic viral diseases. Its pipeline produc …
  • ProMIS Neurosciences Inc (PMN):医療機器:M&Aディール及び事業提携情報
    Summary ProMIS Neurosciences Inc (ProMIS), formerly Amorfix Life Sciences Ltd is a development stage biopharmaceutical company which focuses on the development of therapeutic antibodies and diagnostics for the treatment of misfolded protein diseases. The company uses ProMIS technology, helps in pred …
  • Ascential plc:企業の戦略・SWOT・財務情報
    Ascential plc - Strategy, SWOT and Corporate Finance Report Summary Ascential plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Atlantic Power Corporation:企業の発電所・SWOT分析2018
    Atlantic Power Corporation - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key em …
  • Acadia Healthcare Company Inc:企業のM&A・事業提携・投資動向
    Acadia Healthcare Company Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Acadia Healthcare Company Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • MCC EuroChem:企業の戦略的SWOT分析
    MCC EuroChem - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • 4SC AG (VSC):製薬・医療:M&Aディール及び事業提携情報
    Summary 4SC AG (4SC) is a biopharmaceutical company that discovers and develops small molecule drugs for the treatment of cancer and autoimmune diseases. The company’s product focuses on epigenetics, cancer stem cells and cancer immunotherapy. Its product pipeline comprises therapeutic programs at v …
  • Utair Aviation
    Utair Aviation - Strategy, SWOT and Corporate Finance Report Summary Utair Aviation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Stellar Biotechnologies Inc (SBOT)-製薬・医療分野:企業M&A・提携分析
    Summary Stellar Biotechnologies Inc (Stellar Bio), formerly CAG Capital Inc is a provider of keyhole limpet hemocyanin proteins. The company offers potent immune-stimulating molecule used as an active pharmaceutical ingredient known as active immunotherapies or therapeutic vaccines and as an injecta …
  • Pear Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Pear Therapeutics Inc (Pear Therapeutics) develops software-based prescription digital therapeutics for the treatment of severe medical conditions and diseases. Its product pipeline includes reSET-O for treating opioid use disorder (OUD) in conjunction with opioid replacement therapy; Thrive …
  • Ekarat Engineering (Public) Co., Ltd. (AKR):企業の財務・戦略的SWOT分析
    Ekarat Engineering (Public) Co., Ltd. (AKR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • Elektrani na Makedonija:企業の戦略的SWOT分析
    Elektrani na Makedonija - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆